secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001564590-21-039201
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion Q2 net loss $16.2M; cash $70M; pipeline advances; praliciguat licensed to Akebia for up to $585M milestones
--------------------------------------------------------------------------------

- Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.
- CY6463 Phase 2a trial initiated in Alzheimer's with vascular pathology (ADv); Ph1b in CIAS start-up; MELAS data expected by year-end 2021.
- Exclusive global license of praliciguat to Akebia Therapeutics; Cyclerion eligible for up to $585M milestones plus tiered royalties.
- Closed $18M private placement with EcoR1, Slate Path, MFN, Invus, and others; net $12.5M from ATM offering in Q2.
- Errol De Souza appointed to Board of Directors; expanded Beacon Biosignals partnership for biomarker identification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/0001564590-21-039201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/cycn-8k_20210729.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-039201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer